A Multiple Ascending Dose Study of HTD1801 in Adults With Hypercholesterolemia
Status:
Completed
Trial end date:
2018-12-31
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-controlled, multicenter, multiple ascending dose
(MAD) study to evaluate the safety and tolerability, PK, and PD profiles of HTD1801 in
overweight to obese adults with hypercholesterolemia. There will be 3 cohorts of dose levels
as 500, 1000 and 2000mg/day, 16 subjects for each cohort with 12 subjects will administer
HTD1801 and 4 subjects will administer Placebo.